Asensus Surgical, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) — Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company […]
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
MANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company […]
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases
– In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown – – All Evaluable […]
NIO Inc. Announces Repurchase Right Notification for 0.00% Convertible Senior Notes due 2026
SHANGHAI, China, Jan. 03, 2024 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), […]
Ragnarok X : Next Genration Received a ISBN Code by Chinese Government
Seoul, Jan. 03, 2024 (GLOBE NEWSWIRE) — GRAVITY Co., Ltd. (NasdaqGM: GRVY) (“Gravity” or “Company”), a developer and publisher of […]
Radware Schedules Conference Call for Its Fourth Quarter and Full Year 2023 Earnings
TEL AVIV, Israel, Jan. 03, 2024 (GLOBE NEWSWIRE) — Radware® (NASDAQ: RDWR), a leading provider of cyber security and application […]
Enovis Completes Acquisition of LimaCorporate S.p.A
WILMINGTON, Del., Jan. 03, 2024 (GLOBE NEWSWIRE) — Enovis™ Corporation (NYSE: ENOV, “Enovis” or the “Company”) an innovation-driven, medical technology […]
Lancaster Resources Announces Spin-Off Agreement with Subsidiary and Record Date
VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) — Lancaster Resources Inc. (CSE:LCR | OTCQB:LANRF | FRA:6UF0) (the “Company”) announces […]
CRYPTOBLOX PROVIDES YEAR END SUMMARY AND CORPORATE UPDATE
Vancouver, B.C., Jan. 03, 2024 (GLOBE NEWSWIRE) — CryptoBlox Technologies Inc. (the “Company” or “CryptoBlox”) (CSE: BLOX) wishes everyone a […]
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
The confirmatory clinical, safety and efficacy study for AVT06, biosimilar candidate to Eylea® (aflibercept) met its primary endpoint in patients […]
